FNDC3A

Across TCGA pan-cancer cohorts, FNDC3A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FNDC3A data layer compared with 30 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher FNDC3A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FNDC3A expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where FNDC3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.657	0.884	.008	14	view →
LUAD	OS	Tertile	All	0.920	1.000	.025	4	view →
PDAC	OS	Quartile	II,III,IV	0.880	0.709	.039	3	view →
CCRCC	DFS	Quartile	III,IV	0.222	0.830	.038	3	view →
GBM	OS	Median	All	0.655	0.870	.011	2	view →
HNSC	DFS	Quartile	III,IV	0.690	0.933	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FNDC3A–LSCC (DFS)

Open the LSCC breakdown →